Where does Epimmune Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Epimmune Inc. ranks #46,544 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Epimmune Inc. hold?

Epimmune Inc. holds 5 US utility patents granted between 2016 and 2017, spanning 5 technology areas.

What is Epimmune Inc.'s Innovation Score?

Epimmune Inc. has an Innovation Score of 19.1 out of 100 (6th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Epimmune Inc. focus on?

Epimmune Inc.'s top technology area is C07K (Peptides) with 5 patents, ranking #1,584 of 3,615 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Epimmune Inc.'s patent grant rate increasing or decreasing?

Epimmune Inc.'s recent grant velocity is -100% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Epimmune Inc.'s patents?

Epimmune Inc.'s patents average 8.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Epimmune Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Epimmune Inc.

USPTO PatentsView assignee record - 5 granted patents across 5 technology areas, recorded in grant years 2016–2017. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Epimmune ranks #46,544 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 5 technology areas.

#46,544
of 49,997 US assignees by volume: 6th percentile
by Innovation Score (19.1/100): 8.4
avg claims per patent: -100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R46544 · US Corporation #46,544 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-LOW · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 5 grants
BOTTOM-DECILE #46,544/49,997
PHOTO-FINISH Epiance Software PVT
CPC-NARROW C07K · 5 areas
INNOV-LOW 19.1/100
CLAIMS-PAR 8.4 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Epiance Software PVT. Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Epimmune’s 19.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (32%) Velocity 0.0 pts (0%) Breadth 7.9 pts (41%) Claim depth 5.0 pts (26%)

Qualcomm Incorporated · highest

85
Epimmune · this assignee

19
3D Lighting… · lowest

7

What this shows Epimmune's Innovation Score is 19.1/100 (6th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Epimmune?

Each dot is one of Epimmune’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Epimmune’s own 8.4 claims/patent is at or below the 19.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Epimmune vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Epimmune's grants concentrate

Epimmune Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2016 (4 grants) versus a trough of 1 in 2017. By volume, Epimmune sits between Epiance Software PVT. Ltd. and Ergo Exergy Technologies Inc..

Epiance Software…

5
Epic Medical PTE

5
Epic Sciences

5
Epigan

5
Epitech MAG

5
Equus UK Topco

5
Era3

5
Ergo Exergy

5
Epimmune ◀

5

What this shows Epimmune holds 5 patents at rank #46,447, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Epimmune

By rank, the assignees closest to #46,447 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Epimmune's primary technology class.

Epimmune's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

19 6th percentile higher than 6% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2017

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Epimmune Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	4	80.0%
2017	1	20.0%

Which technologies does Epimmune Inc. patent most?

C07K - Peptides 5

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 3

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 3

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Epimmune Inc.'s patent record in context - here's where to go next.

Epimmune Inc.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #46,544 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Epimmune Inc. against Epiance Software PVT. Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 19.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.